The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2020 ASCO NSCLC Highlights: Can We Consider Nivo + Ipi a Novel Chemo-Sparing 1L Option for Advanced Disease? How Effective is Tiragolumab Addition to Atezo in 1L PD-L1 Disease?

142 views
September 9, 2020
Comments 0
Login to view comments. Click here to Login